Lipocine initiated with a Buy at Alliance Global Partners

Alliance Global Partners analyst Scott Henry initiated coverage of Lipocine with a Buy rating and $10 price target. Lipocine utilizes its Lip’ral delivery platform to develop improved profiles for known molecules, which includes on-market products such as Tlando, late-stage development candidates like LPCN 1154 and earlier stage compounds such as LPCN 2401, the analyst noted. The firm’s Buy rating is based on the belief that LPCN 1154 for postpartum depression is “approvable and could generate significant revenues,” notes the firm, which also sees “significant upside potential” from the company’s LPCN 2401 obesity compound that could be taken in combination with GLP-1 drugs.